A
Arthur A. Levin
Researcher at Isis Pharmaceuticals
Publications - 101
Citations - 9605
Arthur A. Levin is an academic researcher from Isis Pharmaceuticals. The author has contributed to research in topics: Pharmacokinetics & Retinoic acid. The author has an hindex of 45, co-authored 100 publications receiving 8914 citations. Previous affiliations of Arthur A. Levin include Hoffmann-La Roche & Santaris Pharma a/s.
Papers
More filters
Journal ArticleDOI
Treatment of HCV Infection by Targeting MicroRNA
Harry L.A. Janssen,Hendrik W. Reesink,Eric Lawitz,Stefan Zeuzem,Maribel Rodriguez-Torres,Keyur Patel,Adriaan J. van der Meer,Amy K. Patick,Alice Chen,Yi Zhou,Robert Persson,Barney D King,Sakari Kauppinen,Arthur A. Levin,Michael R. Hodges +14 more
TL;DR: The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance.
Journal ArticleDOI
9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha.
Arthur A. Levin,Laurie J. Sturzenbecker,Sonja Kazmer,Thomas Bosakowski,Christine Huselton,Gary Allenby,J Speck,C Kratzeisen,Michael Rosenberger,Allen John Lovey +9 more
TL;DR: The identification of a stereoisomer of retinoic acid, 9-cis retinol, which directly binds and activates RXRα, which suggests a new role for isomerization in the physiology of natural retinoids.
Journal ArticleDOI
Developing MicroRNA Therapeutics
TL;DR: This review serves to provide some general insight into some of the current micro RNAs targets, how one goes from the initial bench discovery to actually developing a therapeutically useful modality, and will briefly summarize the current patent landscape and the companies that have started to explore microRNAs as the next drug target.
Journal ArticleDOI
A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
Journal Article
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
Richard S. Geary,Tanya A. Watanabe,LoAnne Truong,Sue Freier,Elena A. Lesnik,Namir Sioufi,Henri Sasmor,Muthiah Manoharan,Arthur A. Levin +8 more
TL;DR: A balance of greater stability supplied by the 2'-O-MOE modification together with maintenance of plasma protein binding appears to be necessary to ensure favorable pharmacokinetics of this new generation of antisense oligonucleotides.